These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 1378351)

  • 21. Melanoma antigens: immunological and biological characterization and clinical significance.
    Herlyn M; Koprowski H
    Annu Rev Immunol; 1988; 6():283-308. PubMed ID: 3289568
    [No Abstract]   [Full Text] [Related]  

  • 22. Cancer immunotherapy with autologous and allogeneic vaccines: a practical overview.
    Shinitzky M; Skornick Y
    Prog Clin Biol Res; 1990; 348():95-125. PubMed ID: 2201036
    [No Abstract]   [Full Text] [Related]  

  • 23. The immunogenic properties of melanoma-associated antigens recognized by cytotoxic T lymphocytes.
    Kirkin AF; Dzhandzhugazyan K; Zeuthen J
    Exp Clin Immunogenet; 1998; 15(1):19-32. PubMed ID: 9619397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Discovery of the splicing of peptides by the proteasome and study of preclinical models of anticancer immunotherapy].
    Van den Eynde B
    Bull Mem Acad R Med Belg; 2007; 162(5-6):352-6. PubMed ID: 18405005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of a tumor associated antigen that can induce tumor specific cytotoxicity.
    Dunkle A; He YW
    Cancer Biol Ther; 2009 May; 8(9):844-5. PubMed ID: 19377280
    [No Abstract]   [Full Text] [Related]  

  • 26. Future directions in tumor immunotherapy: CTLA4 blockade.
    Gulley JL; Dahut WL
    Nat Clin Pract Oncol; 2007 Mar; 4(3):136-7. PubMed ID: 17327854
    [No Abstract]   [Full Text] [Related]  

  • 27. Analysis of hybridoma-exchange antibodies.
    Lloyd KO; Albino A; Houghton A
    Hybridoma; 1982; 1(4):461-3. PubMed ID: 6208140
    [No Abstract]   [Full Text] [Related]  

  • 28. Tumor antigens recognized by T lymphocytes.
    Boon T; Cerottini JC; Van den Eynde B; van der Bruggen P; Van Pel A
    Annu Rev Immunol; 1994; 12():337-65. PubMed ID: 8011285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Augmentation of T-cell response with a melanoma cell vaccine expressing specific HLA-A antigens.
    Hoon DS; Morisaki T; Uchiyama A; Hayashi Y; Foshag LJ; Nizze AJ; Morton DL
    Ann N Y Acad Sci; 1993 Aug; 690():343-5. PubMed ID: 8368751
    [No Abstract]   [Full Text] [Related]  

  • 30. Virus augmentation of the antigenicity of tumor cell extracts.
    Austin FC; Boone CW
    Adv Cancer Res; 1979; 30():301-45. PubMed ID: 92181
    [No Abstract]   [Full Text] [Related]  

  • 31. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.
    Peggs KS; Quezada SA; Korman AJ; Allison JP
    Curr Opin Immunol; 2006 Apr; 18(2):206-13. PubMed ID: 16464564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CTLA-4 blockade: autoimmunity as treatment.
    Kapadia D; Fong L
    J Clin Oncol; 2005 Dec; 23(35):8926-8. PubMed ID: 16204008
    [No Abstract]   [Full Text] [Related]  

  • 33. [New aspects of tumor immunology. Importance of the T-cell system].
    Knuth A; Dippold W; Meyer zum Büschenfelde KH
    Dtsch Med Wochenschr; 1982 Jul; 107(28):1105-10. PubMed ID: 6177489
    [No Abstract]   [Full Text] [Related]  

  • 34. Antigenic profile of human melanoma cells. Analysis with monoclonal antibodies to histocompatibility antigens and to melanoma-associated antigens.
    Natali PG; Giacomini P; Russo C; Steinbach G; Fenoglio C; Ferrone S
    J Cutan Pathol; 1983 Aug; 10(4):225-37. PubMed ID: 6350388
    [No Abstract]   [Full Text] [Related]  

  • 35. [Targeting cancer antigen (MAGE-A4, NY-ESO -1) for immunotherapy].
    Imai N; Ikeda H; Shiku H
    Nihon Rinsho; 2012 Dec; 70(12):2125-9. PubMed ID: 23259384
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The structure and function of MHC molecules. Possible implications for the control of tumor growth by MHC-restricted T cells.
    Kourilsky P; Jaulin C; Ley V
    Semin Cancer Biol; 1991 Oct; 2(5):275-82. PubMed ID: 1773044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccines against advanced melanoma.
    Blanchard T; Srivastava PK; Duan F
    Clin Dermatol; 2013; 31(2):179-90. PubMed ID: 23438381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Second international symposium on alien histocompatibility antigens on cancer cells. October 8-11, 1980, Racine, Wisconsin.
    Transplant Proc; 1981 Dec; 13(4):1751-999. PubMed ID: 6120592
    [No Abstract]   [Full Text] [Related]  

  • 39. TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity.
    Stone JD; Harris DT; Kranz DM
    Curr Opin Immunol; 2015 Apr; 33():16-22. PubMed ID: 25618219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure and epitope specificity of human melanoma-associated oncofetal antigen gp87 analyzed with monoclonal antibodies.
    Liao SK; Leung WC; Kanamaru T
    J Dermatol; 1985 Apr; 12(2):117-28. PubMed ID: 2411774
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.